aTYR PHARMA (ATYR) Operating Leases (2019 - 2026)
aTYR PHARMA's (ATYR) quarterly Operating Leases came in at $10.1 million in Q1 2026, down 8.13% YoY from $11.0 million in Q1 2025, and down 2.38% on a QoQ basis from $10.3 million in Q4 2025.
aTYR PHARMA (ATYR) Operating Leases (2019 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 8 years of Operating Leases data on file, last reported at $10.1 million in Q1 2026.
- Quarterly Operating Leases fell 8.13% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (down 8.13% YoY) and the FY2025 annual result came in at $10.3 million, down 7.5% from the prior year.
- Operating Leases fell to $10.1 million in Q1 2026, from $10.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $12.8 million in Q2 2023 to a low of $133000.0 in Q1 2022.
- A 5-year average of $10.3 million and a median of $11.0 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases tumbled 88.38% — and 2023, when it soared 8859.4%.
- Tracing ATYR's Operating Leases over 5 years: stood at $9.6 million in 2022, then gained by 28.09% to $12.3 million in 2023, then slipped by 9.68% to $11.1 million in 2024, then decreased by 7.5% to $10.3 million in 2025, then decreased by 2.38% to $10.1 million in 2026.
- The last three Operating Leases figures came in at $10.1 million (Q1 2026), $10.3 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.80 Mn |
| Mar 31, 2026 | 10.06 Mn |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 10.53 Mn |
| Jun 30, 2025 | 10.75 Mn |
| Mar 31, 2025 | 10.95 Mn |
| Dec 31, 2024 | 11.14 Mn |
| Sep 30, 2024 | 11.33 Mn |
| Jun 30, 2024 | 11.51 Mn |
| Mar 31, 2024 | 11.69 Mn |
| Dec 31, 2023 | 12.34 Mn |
| Sep 30, 2023 | 12.55 Mn |
| Jun 30, 2023 | 12.80 Mn |
| Mar 31, 2023 | 11.92 Mn |
| Dec 31, 2022 | 9.63 Mn |
| Sep 30, 2022 | 7.22 Mn |
| Mar 31, 2022 | 133,000.00 |
| Dec 31, 2021 | 398,000.00 |
| Sep 30, 2021 | 657,000.00 |
| Jun 30, 2021 | 906,000.00 |